Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14743 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von Stephen D Silberstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Migraine Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Objective To characterize the long‐term (56‐week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
- Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA.
- Atria Academy of Science and Medicine, New York, New York, USA.
- Allergan, an AbbVie Company, Irvine, California, USA.
- Department of Neurology, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA.
ORCID-Profile: David W Dodick, Richard B Lipton
Förderung
- AbbVie
Zitieren
APA
Silberstein, S. D., Diener, H. C., Dodick, D. W., Sommer, K., & Lipton, R. B. (2024). Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14743
Vancouver
Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14743
BibTeX
@article{Silberstein2024,
author = {Silberstein, Stephen D and Diener, Hans-Christoph and Dodick, David W and Sommer, Katherine and Lipton, Richard B},
title = {Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14743}
}
EUVIMED